Insurers see the potential for AI to reduce employers’ healthcare costs, but fear that new technology and treatments could create further spending pressures, a report has found. 

Employers face another year of increases in the cost of providing medical cover for their staff, despite hopes that AI could help insurers make savings.

The Health Trends 2027 report, from global professional services firm Marsh, draws on responses from 306 insurers across 69 markets. It examines the pressures driving up the cost of employer-sponsored medical plans and how businesses can manage their spending on health benefits.

Some 55% of insurers expect AI to reduce the overall cost of their group medical plans over the next two to three years by, for example, reducing administrative tasks. However, others fear that the cost of buying and implementing AI could increase expenditure overall. As well as this, more than a third expect the technology to identify smaller abnormalities that might otherwise go unnoticed, potentially prompting additional tests and procedures and thereby increasing costs. 

These pressures come against a backdrop of persistently high increases in the cost of employer-sponsored medical plans. In the UK, medical claims costs per person covered by a medical scheme are forecast to rise by 9% in 2027, up from 8% in 2026, according to Marsh. Globally, the forecast is for 10.1%, up from 10%, excluding the US. 

Support across cancer treatment

Commenting on the UK perspective, Nick McMenemy, Marsh’s UK health and benefits leader, said tackling the causes of poor health earlier, with shared responsibility between the state, employers and individuals, would be key to containing medical trend rates and improving population health.

Cancer is one of the biggest sources of claims spending for employer-sponsored plans, with seven in ten insurers ranking it among the three leading causes of claims by value in 2025. However, fewer than half of insurers typically cover preventive cancer screening through these plans, highlighting gaps in access to early detection.

Lorna Friedman, senior partner for health transformation and sustainability at Marsh Health and Benefits, said employers needed to consider support across the whole cancer journey, from prevention and screening to treatment, returning to work and ongoing care for survivors.

“The employers that understand their risks and options will be better positioned to manage costs and support their people when it matters most,” Friedman said.

The report says earlier cancer detection can improve outcomes and reduce the need for more complex and expensive treatment, highlighting the potential value of prevention and screening for employers and their workforce.